NDAORALCAPSULEPriority Review
Approved
Oct 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
49
Data completeness
5/8 — Partial
Priority Review
TALZENNA (talazoparib) by Pfizer. Approved for breast cancer, prostate cancer. First approved in 2018.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALZENNA (talazoparib) is an oral small-molecule PARP inhibitor approved by the FDA in October 2018 and currently at peak lifecycle stage. It is indicated across 24 cancer types spanning solid tumors (breast, ovarian, prostate, pancreatic, lung, head and neck) and hematologic malignancies (AML, NHL, multiple myeloma), as well as rare pediatric and adult sarcomas. As a PARP inhibitor, talazoparib impairs DNA repair in homologous recombination-deficient tumors, particularly those with BRCA mutations. The drug occupies a competitive position within the expanding PARP inhibitor class for oncology.
$0.0BPart D
5.5 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (2)
Clinical Trials (49)
Korea Post Marketing Surveillance (PMS) Study of Talzenna®
Started Jun 2027
600 enrolled
Breast Neoplasms
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Started May 2026
126 enrolled
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.
Started Jul 2025
1 enrolled
Prostate Cancer
A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer
Started Apr 2025
3 enrolled
Breast Cancer
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Started Apr 2023
33 enrolled
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Worked on TALZENNA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.